Skip to main content

Table 2 Efficacy of treatment with either mFOLFOX-6 plus cetuximab (FOLFOX + Cmab) or XELOX plus cetuximab (XELOX + Cmab)

From: Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study

  All patients (n = 62) FOLFOX + Cmab (n = 37) XELOX + Cmab (n = 25)
Tumor response    
 CR 2 2 0
 PR 40 22 18
 SD 15 9 6
 PD 3 2 1
 NE 2 2 0
Response rate (%) 67.7 (54.7–79.1) 64.9 (47.5–79.8) 72.0 (50.6–87.9)
DCR (%) 91.9 (82.3–97.3) 89.2 (74.6–97.0) 96.0 (79.7–99.9)
Median PFS (months) 13.4 (12.1–17.5) 13.1 (11.4–18.3) 13.4 (10.1–17.9)
Median OS (months) 38.1 (30.3–45.8) 38.1 (33.5–42.6) 47.0 (32.1–61.9)
  1. Data are given as the number of patients in each group or as median values with 95 % confidence intervals in parentheses
  2. CR complete response, PR partial response, SD stable disease, PD progressive disease, NE not evaluated, DCR disease control rate, PFS progression free survival; OS, overall survival